dose-dense MVAC cohort compared with 13.2% in the standard MVAC cohort; one toxic death occurred in each arm, but less overall toxicity was seen in the dose-dense group. Based on these data, standard MVAC is inferior to high-dose-intensity MVAC in terms
Peter E. Clark, Neeraj Agarwal, Matthew C. Biagioli, Mario A. Eisenberger, Richard E. Greenberg, Harry W. Herr, Brant A. Inman, Deborah A. Kuban, Timothy M. Kuzel, Subodh M. Lele, Jeff Michalski, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Jerome P. Richie, Wade J. Sexton, William U. Shipley, Eric J. Small, Philippe E. Spiess, Donald L. Trump, Geoffrey Wile, Timothy G. Wilson, Mary Dwyer and Maria Ho
Susan O'Brien, Camille N. Abboud, Mojtaba Akhtari, Jessica Altman, Ellin Berman, Daniel J. DeAngelo, Steven Devine, Amir T. Fathi, Jason Gotlib, Madan Jagasia, Joseph O. Moore, Javier Pinilla-Ibarz, Jerald P. Radich, Vishnu V.B. Reddy, Neil P. Shah, Paul J. Shami, B. Douglas Smith, David S. Snyder, Meir Wetzler and Furhan Yunus
. 40%, respectively; CCyR, 70% vs. 66%, respectively). In patients with high Sokal risk scores, MMR rates at 12 months were 51% for high-dose imatinib compared with 31% for standard-dose. The MMR rate also correlated with average dose intensity. At 12
Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Celeste M. Bello, Philip J. Bierman, Kristie A. Blum, Bouthaina Dabaja, Ysabel Duron, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, David G. Maloney, David Mansur, Peter M. Mauch, Monika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Matthew Poppe, Barbara Pro, Lawrence Weiss, Jane N. Winter and Joachim Yahalom
.They also showed that the use of growth factors with chemotherapy significantly increases the incidence of BPT (26% vs. 9%). Recently, 2 separate studies confirmed that ABVD chemotherapy can be safely administered at the full dose intensity without any
Susan O'Brien, Ellin Berman, Hossein Borghaei, Daniel J. DeAngelo, Marcel P. Devetten, Steven Devine, Harry P. Erba, Jason Gotlib, Madan Jagasia, Joseph O. Moore, Tariq Mughal, Javier Pinilla-Ibarz, Jerald P. Radich, Neil P. Shah, Paul J. Shami, B. Douglas Smith, David S. Snyder, Martin S. Tallman, Moshe Talpaz and Meir Wetzler
Selectivity) study [abstract] . Blood 2008 ; 112 : Abstract 335 . 61 Hughes TP Branford S White DL . Impact of early dose intensity on cytogenetic and molecular responses in chronic phase CML patients receiving 600 mg/day of imatinib as initial
Michael D. Stubblefield, Harold J. Burstein, Allen W. Burton, Christian M. Custodio, Gary E. Deng, Maria Ho, Larry Junck, G. Stephen Morris, Judith A. Paice, Sudhakar Tummala and Jamie H. Von Roenn
multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer . J Clin Oncol 2000 ; 18 : 136 – 147 . 19 Maindrault-Goebel F de Gramont A Louvet C . High-dose
Ludmila Katherine Martin and Tanios Bekaii-Saab
in long-term clinical outcomes (such as disease-free and overall survivals) with prolonged follow-up from phase III trials, its integration into standard neoadjuvant CRT should then be considered. However, maintaining dose intensity may prove
Louis Burt Nabors, Jana Portnow, Mario Ammirati, Joachim Baehring, Henry Brem, Paul Brown, Nicholas Butowski, Marc C. Chamberlain, Robert A. Fenstermaker, Allan Friedman, Mark R. Gilbert, Jona Hattangadi-Gluth, Matthias Holdhoff, Larry Junck, Thomas Kaley, Ronald Lawson, Jay S. Loeffler, Mary P. Lovely, Paul L. Moots, Maciej M. Mrugala, Herbert B. Newton, Ian Parney, Jeffrey J. Raizer, Lawrence Recht, Nicole Shonka, Dennis C. Shrieve, Allen K. Sills Jr, Lode J. Swinnen, David Tran, Nam Tran, Frank D. Vrionis, Stephanie Weiss, Patrick Yung Wen, Nicole McMillian and Anita M. Engh
high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma . Int J Radiat Oncol Biol Phys 2014 ; 88 : 793 - 800 . 61. Ney DE Carlson JA Damek DM . Phase II trial of
Paolo Marchetti, Raymond Voltz, Carmen Rubio, Didier Mayeur and Andreas Kopf
from supportive care or supportive therapies , which are prescribed to treat the side effects of disease-specific treatment or to allow for higher doses or dose intensities of the treatment to be delivered. A common understanding of the services
Boglarka Gyurkocza and Frederick R. Appelbaum
: the role of dose intensity . Leukemia 2006 ; 32 : 322 – 328 . 18. McClune B Weisdorf DJ DiPersio JF . Non-myeloablative hematopoietic stem cell transplantation in older patients with AML and MDS: results from the Center for International Blood and
Bhumsuk Keam, Jeong-Hoon Lee, Seock-Ah Im and Jung-Hwan Yoon
prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with non-Hodgkin’s lymphoma who receive cytotoxic chemotherapy . J Korean Med Sci 2003 ; 18 : 849 – 854 . 114 Leaw